Anthem Biosciences Share Price Target / Forecast (2026–2040)

Anthem Biosciences Share Price Target

Before understanding the Anthem Biosciences share price target, let us first understand the basic nuances of the company, including its history, business model, background, financial information, and other key factors.

🏢 Company Snapshot

ParameterDetails
Company NameAnthem Biosciences Ltd
IndustryCRDMO (Contract Research, Development & Manufacturing Organization)
Founded2006
HeadquartersIndia
Key ProductsAPIs, enzymes, biosimilars, peptides, vitamin analogues, probiotics
PromotersAjay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, Ishaan Bhardwaj
Pre-IPO Shareholding76.87%
Post-IPO Shareholding74.68%
Customers550+ in 44 countries

💰 IPO Summary

ParameterDetails
Issue Size₹3,395.79 Cr
Shares Offered5.96 Crore
Type100% Offer for Sale
Issue Price₹570
Face Value₹2
Lot Size (Retail)26 Shares
Listing DateJuly 21, 2025
Listing ExchangesBSE, NSE
RegistrarKFin Technologies Ltd
Lead ManagerJM Financial

📊 IPO Subscription Data

CategorySubscription (x)Shares OfferedShares Bid
QIB192.80x1.19 Cr229.1 Cr
NII (Total)44.70x89.1 Lakh39.84 Cr
sNII30.80x29.7 Lakh9.15 Cr
bNII51.66x59.4 Lakh30.69 Cr
Retail5.98x2.08 Cr12.42 Cr
Employee6.99x1.58 Lakh11.08 Lakh
Total67.42x4.17 Cr281.49 Cr
Total Applications37,94,038

📦 Business Overview

SegmentKey OfferingsStrengths
CRDMODrug discovery, development, & manufacturingEnd-to-end pipeline support
Specialty IngredientsFermentation-based APIs, peptides, enzymes, etc.Niche biotech production
Innovation & IP Portfolio7 granted patents (global), 24 pending applicationsDifferentiated tech platform
Client BaseBiotech + Big Pharma (550+ clients in 44 countries)Diversified & global
Team600+ scientists & professionalsStrong R&D foundation

📊 Financial Highlights (₹ in Cr)

MetricFY23FY24FY25CAGR (2Y)
Revenue1,133.991,483.071,930.29~30%
PAT385.19367.31451.26~8.4%
EBITDA446.05519.96683.78~24%
Net Worth1,740.671,924.662,409.86~17%
Total Assets2,014.462,398.112,807.58~18%
Total Borrowing125.06232.53108.95–

📈 Key Performance Indicators

KPIValue
ROE20.82%
ROCE26.88%
PAT Margin23.38%
EBITDA Margin36.81%
Debt-to-Equity0.05
P/E Ratio70.62x
Price/Book Value13.23x
EPS (Pre & Post IPO)₹8.07

🚀 Growth Drivers (2026–2040)

Growth LeverImpactDescription
CRDMO Market ExpansionHighRising global outsourcing of drug R&D
Innovation PipelineHigh24+ patent filings; biosimilars & enzymes
Global Client DiversificationMediumExposure to U.S., EU, Japan
Vertical IntegrationMediumDiscovery to commercial scale
Repeat Client BusinessHighStrong long-term engagements

⚠️ Key Risks

RiskSeverityNotes
High ValuationHighP/E > 70x may limit short-term upside
Offer for Sale OnlyMediumNo fresh capital into business
Regulatory ComplianceMediumRisk in multiple markets, strict R&D norms
IP RiskLow–MediumPatent approvals and pending applications

📊 Investment Outlook Summary

Here’s the Anthem Biosciences Ltd Share Price Target Forecast (2026–2040) assuming a CAGR of 18.215%, starting from a base price of ₹570 (IPO listing price):

📈 Anthem Biosciences Share Price Target (2026–2040)

Anthem Biosciences Share Price Target / Forecast 📊 (2026–2040)

YearPredicted Share Price (₹)Key Assumptions
Anthem Biosciences Share Price Target 2026₹674Robust listing gains; strong IPO subscription reflects investor confidence
Anthem Biosciences Share Price Forecast 2027₹796CRDMO order book expands; high-margin fermentation-based APIs scaling up
Anthem Biosciences Share Price Target 2028₹940Biosimilars and GLP-1 analogs see early commercial adoption
Anthem Biosciences Share Price Forecast 2029₹1,111Long-term contracts with US and EU pharma majors
Anthem Biosciences Share Price Target 2030₹1,312New patents granted; diversification into personalized medicine begins
Anthem Biosciences Share Price Forecast 2031₹1,549Enhanced biotech R&D partnerships with emerging biotech firms
Anthem Biosciences Share Price Target 2032₹1,828Revenue from proprietary molecules and global licensing deals
Anthem Biosciences Share Price Forecast 2033₹2,157Leadership in probiotic APIs; facility expansion in Southeast Asia
Anthem Biosciences Share Price Target 2034₹2,546CRDMO vertical reaches global top-10; integrated digital R&D platforms
Anthem Biosciences Share Price Forecast 2035₹3,005Strategic acquisitions and advanced biologics capacity scaling
Anthem Biosciences Share Price Target 2036₹3,548Anthem enters top-tier biosciences innovation index
Anthem Biosciences Share Price Forecast 2037₹4,191First-in-class biotech product launches; strong cash flows
Anthem Biosciences Share Price Target 2038₹4,945Late-phase clinical pipeline expansion; AI-driven discovery services
Anthem Biosciences Share Price Forecast 2039₹5,837Breakthrough GLP-1 and glycolipid licensing revenue surge
Anthem Biosciences Share Price Target 2040₹6,889Anthem becomes a global leader in CRDMO and biotech innovation

⚠️ Disclaimer

These projections are based on a steady CAGR of 18.215%, derived from assumptions about Anthem Biosciences’ business growth, sector trends, and global expansion. Actual prices may significantly vary depending on financial performance, industry dynamics, regulatory developments, and macroeconomic conditions. Always consult a SEBI-registered investment advisor before taking any position in equities.

Do read our other blogs on our website!

Reliance Industries Share Price Target (2026–2040)

1 thought on “Anthem Biosciences Share Price Target / Forecast (2026–2040)”

  1. Pingback: Aditya Infotech Share Price Target / Forecast (2026–2040) - Price Target

Comments are closed.